Nuvalent logo
Nuvalent
NUVL | NASDAQ
Chart Builder DCF Calculator
$123.96
$0.00 (0.00%)
At close: Jul 14, 2026, 4:00 PM ET

Nuvalent Company Profile

Company profile explained

Company Profile

Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.

Key Executives

Name Position
James R. Porter Chief Executive Officer, President & Director
Alex Balcom Chief Financial Officer & Treasurer
Deborah Ann Miller Chief Legal Officer & Secretary
Benjamin Lane Chief Technical Operations Officer
Chelcie Lister Senior Director of Investor Relations & Corporate Communications
Christopher D. Turner Chief Medical Officer
Darlene Noci Chief Development Officer
Henry Pelish Chief Scientific Officer
John Soglia Senior Vice President of Translational Development
Joshua Horan Senior Vice President of Chemistry
Ruth Adams Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Jul 27, 2026 15-12G Filing
Jul 17, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 17, 2026 4 Filing
Jul 15, 2026 4 Filing
Jul 15, 2026 4 Filing
Jul 15, 2026 4 Filing
Jul 15, 2026 4 Filing
Jul 15, 2026 4 Filing
Jul 15, 2026 4 Filing
Jul 15, 2026 4 Filing
View All SEC Filings ➞
Nuvalent
Nuvalent logo
Country United States
IPO Date Jul 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 234
CEO James R. Porter

Contact Details

One Broadway Cambridge, Massachusetts 02142 United States

Stock Details

Ticker Symbol NUVL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001861560
CUSIP Number 670703107
ISIN Number US6707031075
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.